MindMed commences “Project Angie”: psychedelic drug R&D aimed at treating pain, involving psychedelics including LSD.

Mydecine announces a new partnership with LeadGen Labs, aimed at improving its drug synthesis operations.

UK-based Small Pharma Inc will commence trading on the TSX Venture Exchange (via RTO) on May 6, 2021, under the symbol “DMT”.

Red Light Holland granted patent pending status for its ‘Find Your Dose’ microdosing kit.

Mydecine reports that it’s Phase IIa clinical trial is underway at three sites. Net loss for the year of CAD$26.9 million. Current cash ~CAD$30 million.

A bill filed in Maine would legalize psilocybin mushroom therapy without a medical diagnosis, and allow adults 21-and-older to legally buy the psychedelic and use it under the supervision of a certified psilocybin service practitioner, according to the Dales Report.

Field Trip announces the opening of its 5th new U.S. mental health clinic in Houston.

Novamind is doubling its Cedar Psychiatry network from four to eight locations, estimating a 325% increase in patient visits.

UK-based Small Pharma Inc prepares to go public on the TSXV via RTO, having raised CAD$58 million for its qualifying transaction

MindMed Inc has become the first psychedelics company to successfully uplist to the NASDAQ. Who will be the second…???